GLIS Family Zinc Finger 3 Promotes Triple-Negative Breast Cancer Progression by Inducing Cell Proliferation, Migration and Invasion, and Activating the NF-κB Signaling Pathway
Biological and Pharmaceutical Bulletin · 2023
DOI: 10.1248/bpb.b22-00595 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2023. Verfasst von Chenhao Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Diagnostic and Therapeutic Center for Breast Disease, The Fourth Hospital of Hebei Medical University. Hauptthemen laut MEDLINE: NF-kappa B, Triple Negative Breast Neoplasms, DNA-Binding Proteins, Trans-Activators. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diagnostic and Therapeutic Center for Breast Disease, The Fourth Hospital of Hebei Medical University.
- The Second Department of Thyroid and Breast Surgery, Cangzhou Central Hospital.
- Key Laboratory of Molecular Medicine of Breast Cancer in Hebei.
Zitieren
APA
Li, C., & Geng, C. (2023). GLIS Family Zinc Finger 3 Promotes Triple-Negative Breast Cancer Progression by Inducing Cell Proliferation, Migration and Invasion, and Activating the NF-κB Signaling Pathway. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b22-00595
Vancouver
Li C, Geng C. GLIS Family Zinc Finger 3 Promotes Triple-Negative Breast Cancer Progression by Inducing Cell Proliferation, Migration and Invasion, and Activating the NF-κB Signaling Pathway. Biological and Pharmaceutical Bulletin. 2023. doi:10.1248/bpb.b22-00595
BibTeX
@article{Li2023,
author = {Li, Chenhao and Geng, Cuizhi},
title = {GLIS Family Zinc Finger 3 Promotes Triple-Negative Breast Cancer Progression by Inducing Cell Proliferation, Migration and Invasion, and Activating the NF-κB Signaling Pathway},
journal = {Biological and Pharmaceutical Bulletin},
year = {2023},
doi = {10.1248/bpb.b22-00595}
}
EUVIMED